MICA-129 Val/Met VARIANT ASSOCIATED WITH EPSTEIN-BARR VIRUS COPIES NUMBER IN NASOPHARYNGEAL CARCINOMA
Main Article Content
Abstract
MICA protein (major histocompatibility complex (MHC) class I chain-related A) expressed on cancer and infection cells’s surface, play important role in cancer immune-surveillance via NKG2D receptor activated on NK cells and cytotoxic T cells. Interestingly, a methionine (Met) to valine (Val) substitution at position 129 of the heavy chain domain classified the MICA alleles into strong (MICA-129 Met) and weak (MICA-129Val) binders to NKG2D receptor, previous findings suggested to immune disorders associated with MICA variant. We analyzed on 164 nasopharyngeal carcinoma (NPC) tissues and found Val/Val (33.54%), Val/Met (46.34%) and Met/Met (20.12%), respectively. Allele frequency for Met was 43.29% and for Val was 56.741%. Notably, allele Val strongly related to Epstein-Barr virus (EBV) status in NPC tissues (p=0.04). Our results suggested that the usage of MICA-129 genotype as prognostic marker for immune therapy in the future.
Article Details
References
2. Chen D, Gyllensten U. MICA polymorphism: biology and importance in cancer. Carcinogenesis. 2014;35(12): 2633-2642. doi:10.1093/ carcin/ bgu215
3. Frazao A, Rethacker L, Messaoudene M, et al. NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment. Front Immunol. 2019;10:661. doi:10.3389/ fimmu.2019. 00661
4. Isernhagen A, Malzahn D, Bickeböller H, Dressel R. Impact of the MICA-129Met/Val Dimorphism on NKG2D-Mediated Biological Functions and Disease Risks. Frontiers in Immunology. 2016;7. Accessed July 4, 2023. https://www.frontiersin.org/articles/10.3389/fimmu.2016.00588
5. Tong HV, Toan NL, Song LH, Bock CT, Kremsner PG, Velavan TP. Hepatitis B virus-induced hepatocellular carcinoma: functional roles of MICA variants. Journal of Viral Hepatitis. 2013;20(10):687-698. doi:10.1111/jvh.12089
6. Wielińska J, Tarassi K, Iwaszko M, et al. Shared epitope and polymorphism of MICA and NKG2D encoding genes in Greek and Polish patients with rheumatoid arthritis. Cent Eur J Immunol. 2021;46(1): 92-98. doi:10.5114/ ceji.2021.104425
7. Iwaszko M, Świerkot J, Dratwa M, et al. Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis. Pharmacogenomics J. 2020;20(6):760-769. doi:10.1038/s41397-020-0164-3
8. Zingoni A, Vulpis E, Cecere F, et al. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma. Frontiers in Immunology. 2018;9. Accessed July 5, 2023. https://www.frontiersin.org/ articles/10.3389/fimmu.2018.00926